Pomdoctor Receives Nasdaq Deficiency Notice Over Minimum Bid Price
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from PomDoctor Ltd. Unsponsored ADR ( (POM) ).
On February 2, 2026, Pomdoctor Limited announced that it received a Nasdaq notice dated January 29, 2026, stating that the company’s American depositary shares had traded below the US$1.00 minimum bid price requirement for 33 consecutive business days, putting it out of compliance with Nasdaq’s listing rules. The notice does not immediately affect the listing or trading of Pomdoctor’s ADSs, and the company has been granted a 180-day compliance period until July 28, 2026, to regain compliance, with the possibility of additional time subject to Nasdaq’s determination; Pomdoctor said the deficiency letter will not impact its business operations and that it will take reasonable measures to restore compliance, a development that puts its share price under scrutiny but leaves its underlying online healthcare operations unaffected for now.
The most recent analyst rating on (POM) stock is a Hold with a $0.22 price target. To see the full list of analyst forecasts on PomDoctor Ltd. Unsponsored ADR stock, see the POM Stock Forecast page.
Spark’s Take on POM Stock
According to Spark, TipRanks’ AI Analyst, POM is a Neutral.
The score is driven primarily by weak financial fundamentals (persistent losses and negative equity) and bearish technical momentum (negative MACD, price below key moving averages). Valuation impact is limited because P/E and dividend data were not provided.
To see Spark’s full report on POM stock, click here.
More about PomDoctor Ltd. Unsponsored ADR
Pomdoctor Limited is a leading online medical services platform for chronic diseases in China, ranking sixth in the country’s Internet hospital market by number of contracted doctors in 2022, according to Frost & Sullivan. The company focuses on chronic disease management and pharmaceutical services through a one-stop digital platform that connects patients, doctors, pharmacies, suppliers, and other healthcare participants, with core operations in Internet hospital services and the pharmaceutical supply chain aimed at improving efficiency and transparency in the healthcare value chain.
Average Trading Volume: 2,720,925
Current Market Cap: $27.55M
See more insights into POM stock on TipRanks’ Stock Analysis page.
